Distribution of RANK and RANK Ligand in Normal Human Tissues as Determined by an Optimized Immunohistochemical Method

Area of Science:

• Immunology
• Cell Biology
• Pharmacology

Background:

• Receptor Activator of Nuclear Factor κ B (RANK) and RANK Ligand (RANKL) expression is critical for therapeutic antibodies targeting these molecules.
• Previous studies on RANK and RANKL tissue distribution using various methods have yielded inconsistent findings.
• Validated antibodies and optimized immunohistochemical (IHC) methods are needed for accurate assessment.

Purpose of the Study:

• To generate and validate antibodies against RANK and RANKL.
• To develop and optimize an IHC method for determining RANK and RANKL tissue expression.
• To report the tissue distribution of RANK and RANKL using the optimized assay.

Main Methods:

• Generation of highly specific and validated antibodies for RANK and RANKL.
• Development of an optimized immunohistochemical (IHC) protocol.
• Confirmatory experiments using two independent, validated alternative protocols at separate institutions (USC and Amgen).

Main Results:

• Successfully generated and validated antibodies for RANK and RANKL.
• Established an optimized IHC method for reliable detection of RANK and RANKL.
• Reported the tissue expression patterns of RANK and RANKL based on the optimized IHC assay.

Conclusions:

• The validated antibodies and optimized IHC method provide a reliable tool for studying RANK and RANKL expression.
• Accurate tissue distribution data of RANK and RANKL are essential for the development and clinical application of RANK/RANKL-targeting therapeutics.
• This study addresses inconsistencies in previous literature, providing a foundation for future research in this area.